ArticleFrontiers in public health2026
Factors of post-vaccination serological testing coverage among hepatitis B-exposed children in Fujian, China: a population-based cohort study (2021-2023).
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mother-to-child transmission (MTCT) of the hepatitis B virus (HBV) is still a major public health concern worldwide, especially in high-burden nations like China. In order to assess the effectiveness of children vaccinations and stop MTCT, post-vaccination serological testing (PVST) is crucial. However, there are obstacles to PVST implementation. Objective: The purpose of study is to evaluate the existing local strategies for preventing MTCT and suggest possible improvements by analyzing the dynamics of PVST coverage in children exposed to HBV and the factors that influence it in Fujian Province between 2021 and 2023. Methods: Data from the China Immunization Planning Information System and the China Information System for Prevention of Mother-to-Child Transmission was used in the population-based cohort research. To describe the current status of PVST implementation and find factors linked to it, multivariable logistic regression were used, stratified by high-risk (maternal HBV DNA ≥2 × 10 Results: From 32.4% in 2021 to 79.2% in 2023, PVST coverage rose dramatically, with higher rates among high-risk children (70.5%) than among children with common exposure (53.2%). Failure rates for MTCT dropped from 0.8 to 0.3%. However, the recommended 1-2-month range was exceeded, with over half of children undergoing PVST more than 2 months following immunization. For children with high exposure to HBV, antiviral medication use (OR = 1.575, 95% Conclusions: In terms of PVST coverage and MTCT control, Fujian Province made impressive strides. Maintaining the progress toward MTCT elimination requires the antepartum and postpartum observation periods incorporate a consistent instructional procedure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.